H.C. Wainwright Starts Cara Therapeutics (CARA) at Buy

October 13, 2016 7:28 AM EDT
Get Alerts CARA Hot Sheet
Price: $7.51 -2.85%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 23 | New: 30
Trade CARA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

H.C. Wainwright initiates coverage on Cara Therapeutics (NASDAQ: CARA) with a Buy rating and a price target of $20.00.

Analyst Corey Davis commented, "Drug companies have been seeking the perfect pain treatment for decades—something with mu-opioid-like efficacy (e.g., morphine) with none of the side effects. The ideal product has proven elusive, but Cara's CR845 could come close. Its novelty as one of the first kappa opioid receptor agonists that does not enter the CNS, presents the opportunity to treat peripheral pain without addiction potential. Cara now has shown impressive proof of concept data, but the real clincher should come from the readout of three ongoing Phase 2/3 studies expected in the 1H 2017."

For an analyst ratings summary and ratings history on Cara Therapeutics click here. For more ratings news on Cara Therapeutics click here.

Shares of Cara Therapeutics closed at $7.56 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment